The share of support for each candidate in the 15 most recent polls. About this data Note: The candidates shown are those who have gained the most support in recent polls. Some polls didn’t include ...

The European Commission has approved AstraZeneca’s Trixeo Aerosphere as a maintenance treatment for patients aged 12 and older whose asthma is inadequately controlled with medium-dose ICS/LABA therapy ...

Insmed Incorporated is rated a Buy, driven by Brinsupri’s blockbuster launch and strong TPIP Phase 2b data. Read more on INSM ...

The theme of World Patient Safety Day 2026 is "Safe care for noncommunicable diseases". For people living with long-term conditions, patient safety extends beyond hospitals and health facilities into ...

American Speech-Language-Hearing Association (ASHA)-Defined Hearing Loss Occurred in 24.0% of Patients Versus the ...

Rademikibart meaningfully reduced the rate of treatment failure at 28 days by 66% compared to placebo – –Rademikibart produced a rapid, statistically significant improvement in lung function at Day 7 ...

Rademikibart meaningfully reduced the rate of treatment failure at 28 days by 66% compared to placebo ––Rademikibart produced a rapid, ...

The focus of this latest data presentation was the drug’s efficacy in reducing moderate and severe exacerbations among COPD patients who continued to experience exacerbations despite inhaled ...

Verekitug significantly reduced asthma exacerbations and improved lung function in Phase 2 trials; Phase 3 trials expected in 2027.

Verekitug, 100 mg dosed every 12 weeks, reduced AAER by 56% compared to placebo in patients with severe asthma – – Verekitug also delivered clinically meaningful improvements in lung function (FEV1) ...

aDepartment of Pediatrics, Erasmus University Medical Center Rotterdam, Rotterdam, 3015 GD, Netherlands bDepartment of Pediatrics, Division of Respiratory Medicine and Allergology, Erasmus University ...